Message #39 From:
NewsBot Date: February 23, 2007 04:30:00 AM
ISPH News Inspire to Present Data at 2007 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Inspire scientists and collaborators will present information at the 2007 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting being held February 23 - 27, 2007 in San Diego.
A podium presentation entitled “Anticholinergic Effects of Antihistamine Drugs Used in the Clinic” will be presented by Inspire scientist, Samuel C. Wolff, Ph.D., on Sunday, February 25, 2007 at 2:00 p.m. PT. This presentation addresses the ability of antihistamines to interact with muscarinic receptors, which was evaluated using in vitro studies. The studies focused on the antimuscarinic (potential for drying side effects) activity of various marketed antihistamines including azelastine, cetirizine, desloratadine, fexofenadine, ketotifen and olopatadine, compared to bilastine and epinastine, related compounds in Inspire’s portfolio.
Inspire’s U.S. specialty sales force currently promotes Elestat® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis. Inspire is developing two treatments for allergic rhinitis, including bilastine, an oral antihistamine in Phase 3 development, and epinastine nasal spray, a topical antihistamine in Phase 2 development.
The presentation will be available following the conference on Inspire's website, www.inspirepharm.com, in the Discovery & Development section, under Science & Technology.
About Inspire
Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. The research and development programs of Inspire are driven by extensive scientific experience in the therapeutic areas of ophthalmology and respiratory/allergy, and supported by expertise in the field of P2 receptors. Inspire is currently pursuing programs in bacterial conjunctivitis, dry eye, allergic rhinitis, cystic fibrosis and glaucoma. Inspire’s U.S. specialty sales force promotes Elestat® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis® (cyclosporine ophthalmic emulsion) 0.05% for dry eye, ophthalmology products developed by Allergan, Inc. Elestat and Restasis are trademarks owned by Allergan. AzaSite™ is a trademark owned by InSite Vision Inc. For more information, visit www.inspirepharm.com.
Forward-Looking Statements
The forward-looking statements in this news release relating to management's expectations and beliefs are based on preliminary information and management assumptions. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to product development, revenue, expense and earnings expectations, the seasonality of Elestat, intellectual property rights, adverse litigation developments, adverse developments in the U.S. Securities and Exchange Commission (SEC) investigation, competitive products, results and timing of clinical trials, success of marketing efforts, the need for additional research and testing, delays in manufacturing, funding, and the timing and content of decisions made by regulatory authorities, including the U.S. Food and Drug Administration. Further information regarding factors that could affect Inspire's results is included in Inspire's filings with the SEC. Inspire undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof.
